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The first studies of complement (C) receptor specificity concerned the primate
erythrocyte immune adherence receptor (1) . The erythrocyte immune adherence
receptor was at first thought to be specific for only the C3b fragment of immune
complex-bound C3 (2, 3), but later Cooper demonstrated that immune complex-
bound C4 (C4b) was also bound to erythrocytes (4) . When bone marrow-derived
lymphocytes (B cells) were demonstrated to have C3 receptors, these were at first
thought to be also specific for the C3b fragment of C3 (5) . Later however, B cells
were found to have two different C3 receptors : one which was specific for C3b and
antigenically similar to the erythrocyte immune adherence receptor, and another
which was specific for C3b inactivator-cleaved C3b (CM) and which was not
found on erythrocytes (6) . C3b inactivator is present in serum and has an
enzyme-like activity which cleaves complex-bound C3b into the fragments C3c
and C3d (7) such that the C3c fragment is released from the immune complex
leaving the small C3d fragment complex bound (8) . Recently, it has been shown
that C3b inactivator also cleaves complex-bound C4 . However, the presence of
C2 apparently protects C4 from the action of this inactivator (N . R . Cooper,
personal communication) .
Studies oflymphocytes with C receptors (CRL)1 have indicated thatmany but
not all possessed surface immunoglobulin (SIg), and that depending on the
lymphoid source, some had either one or both types of C3 receptors (6, 9) . Both
types of C3 receptors were usually found on normal lymphocytes . However,
peripheral lymphocytes from most patients with chronic lymphatic leukemia
were found to have a large number of cells with C3d receptors but usually few
cells with immune adherence (C3b) receptors . In 20% of the patients studied,
lymphocyte SIg was found to be missing (9) . Even though lymphocytes with C
receptors and no SIg were rarely found in the peripheral blood of normal
*Supported by a grant from the U . S . Public Health Service (AI-10873) .
f Recipient of a Special Postdoctoral Fellowship from the Leukemia Society of America, Inc .
§ Recipient of a Faculty Research Award from the American Cancer Society (PRA-111) .
'Abbreviations used in this paper: BSA, bovine serum albumin; CLL, chronic lymphatic leuke
mia; CRL, complement receptor lymphocytes; DFP, diisopropylfluorophosphate ; EA, sheep eryth-
rocytes sensitized with yM rabbit antibody to sheep erythrocytes ; EAC, sheep erythrocyte-yM
rabbit antibody-complement complexes ; EA .,;, sheep erythrocytes sensitized with yG rabbit
antibodies ; GVB, gelatin veronal buffer ; HBSS, Hanks' balanced salt solution ; SIg, surface
immunoglobulin ; TRFC, thymus-derived rosette-forming cells (cells havingnonimmune receptors for
sheep erythrocytes .
THE JOURNAL OF EXPERIMENTAL MEDICINE " VOLUME 141, 1975
￿
11631164
￿
SPECIFICITY OF COMPLEMENT RECEPTORS
individuals, 10-20% of spleen lymphocytes were of this type (9). However, since
most of these spleen cells had both the immune adherence (C3b) receptor and the
C3d receptor, it appeared that the type of cells observed in leukemic peripheral
blood was different from any type of normal B cell.
In the present study, lymphocytes, granulocytes, and monocyteswere shown to
possess a receptor activity for C4 which was similar to that previously described
to be present on erythrocytes (4). Specificity of the various lymphocyte C recep-
tors was examined by assays for inhibition of sheep erythrocyte-'YM rabbit anti-
body-C complex (EAC) rosette formation by highly purified C components and
their fragments. By this technique the existence of only two different C receptors
was demonstrated. Utilizing a double-label assay for these two receptors, it was
demonstrated that each of the two types of C receptors could cap independently
and thus were located on different molecules in the B-cell membrane.
Materials and Methods
Blood Cells, Tonsil Cells, and Lymphoblastoid Cell Lines. Blood from normal adults and
patients with a confirmed diagnosis of chronic lymphatic leukemia or Waldenstrom's macro-
globulinemia was collected into heparin. Cultured lymphoblastoid cell lines, except MOLT-4 and
Raji, were initiated from normal buffy coat cellsand were a gift from Dr. Thomas H. Hutteroth, Cor-
nell University Medical College, New York (10) . MOLT-4 lymphoblastoid cells were initiated from
the lymphocytes of a patient with acute lymphoblastic leukemia (11) and were a gift from Dr. Mark
Weksler, Cornell University Medical College, New York. Raji lymphoblastoid cells were initiated
from a patient with Burkitt's lymphoma (12) and were a gift from Dr. Shu Man Fu, The Rockefeller
University, NewYork. Tonsils were obtained from children notknown to have any gross immunolog-
ical defects who were undergoing routine tonsillectomy.
Separation of Lymphocytes.
￿
With normal blood, lymphocytes were isolated by treatment of the
blood with dextran and carbonyl-iron followed by centrifugation on Ficoll-Hypaque at a density of
1.095 g/ml (6).Bloodfrom patients with macroglobulinemia containedlarge numbersof granulocytes
which poorly phagocytized carbonyl-iron. In order to remove granulocytes from these preparations,
the dextran-carbonyl-iron step wasfollowed by centrifugation on Ficoll-Hypaque at adensity of 1.078
g/ml. Lymphocytes from patients with chronic lymphatic leukemia were isolated by Ficoll-Hypaque
(d = 1.078 g/ml) centrifugation without carbonyl-iron pretreatment (6, 9). A similar method was
utilized to remove erythrocytes and granulocytes from tonsil cell suspensions. Macrophage contami-
nation in tonsil cell preparations, as assessed by measuring rosette formation and ingestion of sheep
erythrocytes sensitized with yG rabbit antibody (Ea,,;), was found to be 5% or less .
Separation of Granulocytes and Monocytes.
￿
Granulocyte preparations were the adherent cell
fraction isolated from dextran sedimented blood (6). Monocytes were isolated by adherence in a
similar manner, except that the granulocytes were first removed from the dextran sedimented blood
by bovine serum albumin (BSA) centrifugation (13). Removal of the monocyte-lymphocyte layer
from the BSA with aPasteur pipet wasfacilitated by overlayering the28%BSA with Hanks' balanced
salt solution (HBSS) before centrifugation. Monocyte preparations contained 85-90% monocytes,
6-10% lymphocytes, and 1-5% granulocytes.
Erythrocyte-Antibody-C Complexes (EAC). Sheep erythrocytes sensitized with -yM rabbit
antibody to sheep erythrocytes (EA) were prepared as before (9). EAC14°"Y23hu (prepared with
purified human C components) are designated EAC1-3b and were prepared as previously described
(9) except that the EAC14 used to prepare this complex was produced with only 3.5-7.5 jug C4/109
EACL EAC1-3d, previously designated EAC1-3huIn, were prepared by treating the EAC1-3b with
C3b inactivator (6). The amount of C4 used in the preparation of EAC1-3d wasfound to be critical. If
excess C4 was used, immune adherence activity due to cell-bound C4 remained after repeated
treatments of the EAC1-3b intermediate with C3b inactivator. Since oxidized C2 (14) was used to
form the EAC1-3b, much if not all of the C4 on the EAC was in stable complex with C2 and wasGORDON D . ROSS AND MARGARET J . POLLEY
￿
1165
therefore resistant to the action of the C3b inactivator (N . R. Cooper, personal communication) .
When native C2 was substituted for oxidized C2 in the preparation of the EAC1-3b complex, it was
found that the native C2 offered bound C4 almost as much protection from the action of the C3b
inactivator as did oxidized C2 . The source of C3b inactivator used to prepare the EAC1-3d was either
purified human C3b inactivator (15) or a reagent produced from modified whole human serum . In
order to use the whole humanserum source of C3b inactivator, it wasfound necessary to treat it with
1 M potassium thiocyanate (16), then to heat it 2 h at 56°C, and finally to absorb it with sheep
erythrocytes . In addition, it was also found necessary to remove Cl from the EAC1-3b by incubation
of the complex with 0.04 M EDTA in gelatin veronal buffer (GVB) for 90 min at 37°C . To permit
inactivation of cell-bound C3b, 5 x 10 8 of the EAC4-23b in 1ml of 0.04MEDTA were mixed with 1
ml of the whole serum C3b inactivator reagent for 60 min at 37°C, followed by onewash step in 0.04M
EDTA and two wash steps in GVB . The EAC1-3d, prepared by treatment with purified C3b
inactivator or with the whole serum reagent, were only used as a specific reagent for detection of C3d
receptors when they had been tested and shown in tests for immune adherence with human
erythrocytes to be more than 95% inactivated as compared to the EAC1-3b from which they were
prepared (6) .
Since granulocytes were more sensitive to C4 adherencethan were lymphocytes or monocytes, only
2.5-5,ug C4/108 EAC1 were used during formation of the EAC1-3b when granulocyte receptors were
being assayed . In each experiment, the EAC14 used to prepare the EAC1-3b were tested for lack of
reactivity with the particular type of receptor-bearing cell being examined .
EAC14 were also prepared for detection of C4 receptor activity . These EAC14, in contrast to those
used to prepare theEAC1-3b, were prepared with 100,ug C4/108EAC1, an amount whichwasfound to
be optimal for the detection of all cells having C4 receptor activity .
Detection of CRL, SIg-Bearing Lymphocytes, and Lymphocytes Bearing a Receptor for Sheep
Erythrocytes (TRFC) . CRL, SIg, and thymus-derived rosette-forming cells (TRFC) were assayed as
previously described (6, 9) . CRL or TRFC were also assayed simultaneously with SIg-bearing cells by
double-label assay (9) .
In addition to the usual rosette assay, CRL were assayed by immunofluorescence . 5-10 x 10 8
lymphocytes were suspended in 0.2 ml of either C4, C3b, C3c, or C3d diluted to 5 x 10-'M in 0.03M
NaN,-HBSS . After 15 min incubation at 37°C, the cells were washed three timeswith ice-cold 0.03M
NaNB -HBSS and resuspended in either 0.2 ml of rabbit anti-C4 or 0.2 ml of rabbit anti-C3, each
diluted in 0.03M NaN,-HBSS. After 30 min at 4°C followed by three washes with ice-cold 0.03M
NaNBHBSS, the cells were treated in a similar manner with goat antirabbit -y-globulin conjugated to
fluorescein isothiocyanate and examined for fluorescence by the technique used for assay for SIg (9).
The anti-C4 and anti-C3 used hadbeen prepared by immunization of rabbits with the highly purified
components of C and were known to be monospecific . Before use in these experiments, they were
absorbed with two different lines of cultured lymphoblastoid cells to remove natural antilymphocyte
antibodies . The goat antiserum was purchased from Meloy Laboratories Inc., Springfield, Va ., and
before use was also absorbed with cultured lymphoblastoid cells . In each experiment, as a control, the
lymphocytes without prior exposure to the fluid-phase C components were incubated with the
antisera .
Immune Adherence .
￿
Adherence rosettes of EAC14 or EAC1-3b with human erythrocytes were
quantitated by phase-contrast microscopy (6) .
Detection of Granulocyte and Monocyte C Receptors . Monocytes and granulocytes were as-
sayed for C receptors by an assay for rosette formation with EAC in a similar manner as that pre-
viously described for granulocytes (6) .
Preparation of Purified C Components and their Fragments .
￿
C4 was purified in the usual manner
(17) except that the pseudoglobulin was treated with diisopropylfluorophosphate (DFP) to destroy Cl
esterase (Cls) activity (18) . This pretreatment prevented the conversion of C4 to C4b during the
isolation procedure. The purified C4 gave a single band in polyacrylamide gel electrophoresis and
treatment of a sample of the C4 with purified Cls resulted in displacement of the entire band to
positions characteristic for C4b, demonstrating that all of the untreated C4 was in the native
uncleaved molecular form . C3 was purified in the usual manner (19) and was judged by
polyacrylamide gels to be at least 95% pure and in its unconverted form . C4b wasproduced from C4
by treatment with Cl; followed by addition of DFP to a final concentration of 2 x 10-9 M to
inactivate Cls and then dialysis against veronal-buffered saline . The fragments C3b, C3c, and C3d1166
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were prepared by trypsin cleavage and Sephadex gel filtration accordingto the method of Bokisch et
al. (7). In calculations of molar concentrations the following mol wt were assumed: C4, 200,000
daltons (20); C3, 180,000 daltons; C3b, 173,000daltons; C3c, 150,000 daltons; and Cad, 27,000 daltons
(7).
Purification of Bovine Conglutinin. Conglutinin was purified from adult bovine serum by a
combination of methods described by Lachmann (21). Briefly, conglutinin absorbed onto zymosan
from heat-inactivated serum was eluted with EDTA and precipitated from the eluate as aeuglobulin.
The redissolved euglobulin was first treated with dithiothreitol to reduce contaminating IgM, and
then applied to a Sephadex G-200 column from which it eluted in the excluded volume.
Assayfor Inhibition of CReceptors by Fluid-Phase C.
￿
C receptor target cells were resuspended
at 2 x 10°/ml in a dilution of a particular C component in RPMI-1640 media (Microbiological
Associates, Inc., Bethesda, Md.) . After 10 min at 37°C, the cells were assayed for EAC rosette
formation, either with or withoutfirstwashingaway unbound Cwith ice-cold RPMI-1640. Each of the
different typesof EAC used in this assaywas previously treated with 0.04M EDTA-GVB at 37°C for
90 min to remove C1, thus preventing additional C4 uptake onto theEAC when inhibition wasbeing
measured with fluid-phase native C4.
Since purity of the reagents was essential in this assay, the following control testswere included.
First, the EAC1-3b were tested for contaminating cell-bound C3d. Purified bovine conglutinin,
which specifically agglutinates complexes containing C3d, but not complexes containing only
uncleavedC3b (22),agglutinated EAC1-3dat adilution of 1:6,000 andcompletely inhibited EAC1-3d
rosette formation. However, as expected it neither agglutinated EAC1-3b nor had any effect on
EAC1-3b rosette formation. Next, the C3d preparation was examined for contaminating C3b and
C3c. By both Ouchterlony and immunoelectrophoretic analysis theC3d preparation gave no reaction
with C3c-specific antiserum. Furthermore, the C3d preparation did not inhibit immune adherence
even at adilution of 600,ug/ml, whereas either 60 jg/ml of theC3bpreparation or 150pg/ml oftheC3c
preparation didinhibitimmune adherence. Finally, by Ouchterlony analysis theC3bpreparation did
not contain detectable C3d.
Assay for Inhibition of C Receptors by Antisera . The methods used for the preparation of
antierythrocyte andantilymphocyte sera andforthe assayforinhibition of EACrosetteformation by
these antisera were the same as those previously described (6).
Depletion of TRFC from Peripheral Lymphocytes.
￿
TRFC rosettes were formed as in the TRFC
assay except that the sheeperythrocytes were treated with neuraminidase as described by Weiner et
al. (23) in order to stabilize the rosettes. Rosettes were separated from unrosetted lymphocytes by
centrifugation on Ficoll-Hypaque (d = 1.078 g/ml) by the same method used for isolation of
lymphocytes from peripheral blood (9). Unrosetted lymphocytes (non-TRFC) were removedfrom the
Ficoll-Hypaque interface and washed three times before testing for TRFC contamination. The
TRFC-depleted lymphocyte preparation was usually found to contain between 2 and 5% TRFC.
Results
C4 Receptor Activity on Lymphocytes, Erythrocytes, Granulocytes, and
Monocytes
VARIATION IN THE AMOUNT OF C4 REQUIRED.
￿
EAC14 formed rosettes with various
types of cells. The amount of C4 necessary to detect a maximum number of
rosettes varied considerably with the cell type (Fig. 1). Granulocytes were found
to be more reactive with small amounts of C4 than were erythrocytes. EAC14
prepared with 10 ug C4/109 EAC1 (an amount of C4 calculated to produce
approximately 2,000 molecules of bound C4/EAC14) rosetted only 1-2% of
erythrocytes but 60% of granulocytes (Fig. 1) . The reactivity of both monocytes
and lymphocytes with complex-bound C4 increased over a broad range of C4
input.
SPECIFICITY OF ADHERENCE FOR C4 To ensure that EAC14 did not containGORDON D. ROSS AND MARGARET J . POLLEY
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Titration of C4 by EAC14rosette formation with various types of cells. Two different
lines of cultured lymphoblastoid cells (CLB) were examined. One of the CLB lines (+---+)
formed rosettes with EAC14 prepared with less C4 than did the other CLB line (x---x) . There
was similar variation among different preparations of normal peripheral blood lymphocytes
(NPL). With erythrocytes, immune adherence is expressed as the average number of EAC
bound in rosettes to 100 human erythrocytes (HuE) (O-O rather than as percent rosette
formation.
contaminating C3, the complex was tested with anti-C3. This antibody did not
agglutinate the EAC14 nor did its monovalent fragments (6) inhibit EAC14
rosette formation. The same antibody preparation agglutinated EAC1-3b at a
dilution of 1 :25,000, while a 1 :100 dilution of its monovalent fragments
completely inhibited both EAC1-3b and EAC1-3d rosette formation .
Lymphocytes with C4 Receptor Activity are B Cells
NORMAL LYMPHOCYTES FROM THE BLOOD AND TONSILS . When EAC14 rosette
formation was assayed with normal lymphocytes from the blood or tonsils which
had been previously labeled with fluorescenn-conjugated anti-Ig, most of the
lymphocytes which formed EAC14 rosettes were fluorescent. However, the
peripheral blood C receptor-bearing cells appeared to be a subpopulation of the
SIg-bearing cells, since more than half of the cells which were fluorescence la-
beled with anti-Ig did not form rosettes with any type of EAC (Table I). Occasion-
ally, though, some normal individuals were found who had 1-4% CRL in the
peripheral blood which lacked SIg as detected by immunofluorescence. To
ascertain whether C4 receptor activity was also present on TRFC, experiments
were performed in which a peripheral blood cell population was depleted of
TRFC and the effect of this manipulation on the EAC14 rosette-forming cells was
determined. It was found that depletion of the proportion of peripheral blood
TRFC from 75% to 5% increased the proportion of non-TRFC from 25% to 95% (a
3.8-fold increase) . By this manipulation, the proportion of lymphocytes forming
EAC14 rosettes was increased from 8% to 30% (a 3.75-fold increase) . To
determine whether C4 receptors were on the same lymphocytes as the receptors
for C3, EAC14 was mixed with EAC1-3b or with EAC1-3d. In each case it was
found that only slightly more rosettes formed than when EAC14 was used
individually, indicating that most lymphocytes with C4 receptor activity also
had C3b and C3d receptor activity.
Lymphocyte preparations from tonsils contained more cells with C4 receptor
activity than did peripheral blood lymphocytes and most SIg-bearing tonsil cells1168
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were found to have C receptors (Table I). All tonsil lymphocytes which formed
rosettes with EAC14 also formed rosettes with EAC1-3b and EAC1-3d. However,
tonsil lymphocytes were unlike peripheral blood lymphocytes in that each typeof
EAC detected a number ofCRL on which SIg wasnot detectable by immunofluo-
rescence. EAC14 detected 2-5% SIg-negative CRL in tonsils, while EAC1-3b
detected 3-9% and EAC1-3b detected 9-22%.
LYMPHOCYTES FROM PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES. In four pa-
tients with chronic lymphatic leukemia, most CRL had C3d receptor activity,
but only 10-67% ofthe CRL with C3d receptor activity had C3b receptor activity
and even fewer CRL had C4 receptor activity (Table II). In peripheral
lymphocytes from three patients with Waldenstrom's macroglobulinemia a
higher percentage of cells had Cab and C4 receptor activity than C3d receptor
activity. Futher, two of the patients with macroglobulinemia had some CRL
which did not contain detectable SIg.
LYMPHOBLASTOID CELLS FROM B- AND T-CELL-LIKE LINES .
￿
Lymphoblastoid cells
from only four out of seven B-cell like lines formed rosettes with EAC14, even
Source of
lymphocytes
TABLE I
CRL, SIg, and TRFC in Normal Peripheral Blood and Tonsils
No. of
￿
CRL
samples
￿
SIg
tested
￿
EAC 14
￿
EAC 1-3b
￿
EAC 1-3d
Normal blood
￿
11
￿
9
￿
11
￿
9
￿
26
￿
71
Range
￿
(4-14) (8-16) (4-14) (19-33) (64-79)
Tonsils
￿
8 53 67 71 62 30
Range
￿
(25-75) (42-81) (58-84) (39-78) (15-52)
TABLE II
CRL, SIg, and TRFC in Peripheral Blood Lymphocytes from
Patients with Chronic Lymphatic Leukemia (CLL) and
Waldenstrdm's Macroglobulinemia
TRFC
Disease
EAC14
CRL
EAC1-3b EAC1-3d
SIg TRFC
CLL
H . C. 4 21 31 8 13
F. H. 1 2 25 68 30
L. E. 17 47 85 81 9
H. R. < 1 10 67 74 7
Macroglobulinemia
B. G. 10 27 8 22 66
S. S. 9 4 1 12 76
H. W. 41 32 9 23 40GORDON D. ROSS AND MARGARET J. POLLEY
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though all seven lines formed rosettes with both EAC1-3b and EAC1-3d (Table
III). C4 receptor activity was also found on a small number of cells in the
MOLT-4 line, a line which resembles T cells since it is totally devoid of SIg and
contains TRFC.
Specificity of Lymphocyte C Receptors
INHIBITION OF ROSETTE FORMATION BY FLUID-PHASE C COMPONENTS.
￿
EAC rosette
formation was assayed with C4, C3, and their fragments present in the reaction
mixture. Since a preliminary investigation indicated that there was no signifi-
cantdifference in the degree ofinhibition obtained with native C4 as comparedto
that obtained with C4b, in subsequent inhibition studies only native C4 and not
C4b was utilized. On the other hand, native C3 was not used extensively in the
various inhibition assays because preliminary studies with this component
TABLE III
CRL, SIg, and TRFC in Lymphoblastoid Cells
CRL
indicated that the inhibition by native C3 was not dose dependent over a broad
range of concentrations that were tested (Figs. 2-4).
INHIBITION OF NORMAL LYMPHOCYTE C RECEPTORS. Tonsil lymphocytes were
selected as normal lymphocyte target cells because preparations of these cells
contained more CRL than did peripheral blood lymphocytes. In the tonsil
preparations, more than 50% ofthe cells were found to have receptor activity for
C4, CA, and C3d. The inhibitory effect of C4, C3, and its fragments on rosette
formation with tonsil lymphocytes and EAC was first assayed with the C present
at the time of rosette formation (Figs. 2-4). In order to determine if the C com-
ponents or fragments from the fluid-phase became firmly bound to the specific
receptors, a sample was removed from each complement-lymphocyte suspension
and washed from one to three times before addition of EAC (Table IV).
EAC14 rosette formation was strongly inhibited by fluid-phase C3, C3b, and
C3c, as well as by fluid-phase C4 (Fig. 2 and Table IV). Rosette formation with
EAC1-3b was inhibited by the same fluid-phase components that inhibited
EAC14, except that partial inhibition was consistently observed with fluid-phase
C3d, and fluid-phase C4 and C3c each produced much less inhibition than did
Cell line
EAC14 EAC1-3b EAC1-3d
SIg TRFC
H. H.-O 30 93 91 18 0
H. H.-1 2 89 95 10 0
T. M. 0 77 98 63 0
W.0. 0 29 52 60 0
C. S. 74 79 77 70 0
M. W. 0 70 93 46 0
Wil 3 87 96 35 0
MOLT-4 4 9 83 0 311170
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and their fragments. See legend of Fig. 2 .
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FIG . 2.
￿
Inhibition of EAC14 rosette formation in the presence of various C components and
their fragments . 10 x 10- ' M inhibitor corresponds to 200 jug/ml of C4, 180 pg/ml of C3, 173
,ug/ml of Cab, and 27 Ag/ml of Cad .
o
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FIG. 3.
￿
Inhibition of EAC4°"Y23b rosette formation in the presence of various C components
Concentration of Inhibitor (x107M )
FIG . 4.
￿
Inhibition of EAC4°Iy23d rosette formation in the presence of various C components
and their fragments. See legend of Fig. 2 .
fluid-phase C3b. (Fig . 3 and Table IV) . EAC1-3d rosette formation was inhibited
by fluid-phase C3 and Cad, but some inhibition was also observed with
fluid-phase Cab, while fluid-phase C4 and C3c were without effect (Fig . 4 and
Table IV) .
INHIBITION C RECEPTORS ON ERYTHROCYTES AND LYMPHOBLASTOID CELLS. Lines
C. S. andH. H.-1 were selected as target cells because they had been previously
shown (Table III) to differ in that whereas both lines formed rosettes with EAC1-
3b and EAC1-3d, only C. S . formed a significant number of rosettes with EAC14 .
Erythrocytes were studied because they contained an immune adherence (C3b)
receptor which was antigenically shared with that of lymphocytes, but did not
have a Cad receptor (6) .
With erythrocytes (Table V), EAC1-3b rosette formation (immune adherence)
was inhibited by fluid-phase C3b, C4, and C3c, but not by fluid-phase Cad. The
100
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TABLE IV
Effect of Washing Procedures on the Inhibition of Tonsil Lympho-
cyte C Receptors by Fluid-Phase C Components and C Fragments
Inhibition of rosette formation
* Initial concentrations: C4, 70 gg/ml; C3, 87 pg/ml; C3b, 220gg/ml; C3c,
182 Fg/ml; and Cad, 40 Fg/ml.
$Inhibition of EAC1-3b not obtained with less than 100 Fg/ml of C4.
TABLE V
Inhibition of EACi-3b Rosette Formation by Fluid-Phase
C Components
Inhibition by fluid-phase components*
* Concentrations: C3b, 180 Ag/ml; C4, 200 jag/ml; C3c, 150 ug/ml; and
C3d, 36 jig/ml with lymphoblastoid cells and 75 Ag/ml with human
erythrocytes
1171
lymphoblastoid cell lines differed from each other in that the C . S. line was
inhibited more by fluid-phase C3c than it was by Cad, while the H. H.-1 line was
inhibited more by fluid-phase C3d than it was by CU. Further, C4 was found to
produce greater inhibition with C . S . than with H. H .-1.
INHIBITION OF NORMAL LYMPHOCYTE RECEPTORS FOR THE EAC1-3b.
￿
Normal tonsil
Rosette type Fluid-phase*
component Before
washing
After 1
wash
After 2
washes
After 3
washes
EAC14 C4 99 94 90 83
C3 75 60 52 40
C3b 97 94 93 88
C3c 49 0 - -
C3d 0 - - -
EACi-3b C4 0$ - - -
C3 14 0 - -
C3b 81 54 42 37
C3c 9 0 - -
C3d 21 0 - -
EAC1-3b C4 0 - - -
C3 24 22 14 -
C3d 40 36 15 0
C3c 0 - - -
C3d 77 38 24 21
Target cell
C3b C4 C3c C3d
Humanerythrocytes 56 43 33 0
Lymphoblastoid cells
C. S. line 68 55 28 5
H. H.-1 line 33 10 4 471172
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lymphocytes were examined for inhibition of EAC1-3b rosette formation by C
components and their fragments and by critical combinations of two of these.
The results (Table VI) demonstrated that mixtures of C3c plus C3d and of C4
plus C3d inhibited EAC1-3b rosette formation more strongly than did fluid-
phase C4, C3c, or C3d alone. The inhibition produced with these mixtures was as
much or more than that inhibition produced by an equimolar concentration of
fluid-phase C3b. However, the inhibition produced by a mixture of C4 plus C3c
was not greater than that produced by C3c alone .
INHIBITION OF C RECEPTORS BY ANTISERA. Previously (6) it had been demon-
strated that certain antisera had the ability to inhibit EAC rosette formation .
Antierythrocyte serum inhibited normal lymphocyte rosettes with EACI-3b but
TABLE VI
Inhibition of Tonsil Lymphocyte-EACI-3b Rosette Formation by
Fluid-Phase C
Inhibitor
Inhibition of EAC1-3b rosette formation*
* In the absence of fluid-phase complement, EAC1-3b rosetted 59% of the
tonsil lymphocytes.
$Final concentration of each inhibitor in the mixture.
not with EACI-3d. On the other hand, antichronic lymphatic leukemia lympho-
cyte (anti-CLL) serum inhibited normal lymphocyte rosette formation with
EAC1-3d but not with EAC1-3b . Utilizing these same two antisera in the present
study, it was found that the antierythrocyte but not the anti-CLL serum
inhibited EAC14 rosette formation . Next, the antisera were used to study the C
receptors on H. H.-1 cells and Raji cells . Raji cells resembled H . H.-1 cells in that
they formed rosettes with EACI-3b and EAC1-3d, but not with EAC14 .
Significantly, both of the lines differed from normal lymphocytes in that the
anti-CLL serum inhibited both EAC1-3b (77% and 78%) and EAC1-3d (60% and
69%) rosette formation. Furthermore, the antierythrocyte serum did not inhibit
EAC1-3b rosette formation with either line.
Independent Capping of Different C Receptors
FLUORESCENCE LABELING OF C RECEPTORS.
￿
After washing away unbound fluid-
phase C, the bound components and thus indirectly the C receptors themselves,
10 x 10-'M$ 2.5 x 10-IM
C3b 50 22
C4 24 7
C3c 32 15
Cad 9 5
C3c + C3d 46 40
C4 + Cad 47 33
C3c + C4 30 10
Cab + C4 45 24
Cab + C3d 52 32GORDON D . ROSS AND MARGARET J . POLLEY
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were detected on tonsil lymphocytes by immunofluorescence (Table VII) . Cells
labeled at 4°C in the presence of sodium azide showed an even distribution of
fluorescent patches . When the labeled cells were washed free ofsodium azide and
incubated at 37°C for 30 min, up to50% of the fluorescence-labeled cells exhibited
a redistribution of fluorescence into a single bright polar cap . The specificity of
the fluorescence for CRL was confirmed by assaying fluorescence-labeled cells
for rosette formation with each of the respective EAC complexes . By sequential
observation of the same microscopic field by incident light fluorescence followed
by visible light-phase contrast microscopy, no fluorescence-labeled cells were
found that were not rosetted by EAC .
DOUBLE-LABEL ASSAY FOR CAPPING OF TWO RECEPTORS . By combining the
fluorescence assay for CRL with the rosette assay for CRL, two different C
receptors could be labeled simultaneously on the same lymphocyte .
Cab on tonsil lymphocytes was fluorescence labeled and then induced to form
caps by incubation of the cells at 37°C for 10 min . EAC1-3b were then incubated
TABLE VII
Detection of Tonsil Lymphocyte C Receptors by Immunofluores-
cence vs . EAC Rosette Formation
* FITC, Fuorescenn isothiocyanate-conjugated antibody label .
with the C3b fluorescence-capped lymphocytes for 15 min at 37°C to form
C3b-dependent rosettes . 76% of the C3b fluorescence-capped cells contained an
EAC1-3b rosette which was capped at the same place on the cell membrane as
the fluorescence cap ("cocapping", Fig . 5a) . Furthermore, the distribution of
individual EAC1-3b on lymphocytes was the same as the fluorescence, even on
cells on which the fluorescence was not located in a single cap . For example, when
the fluorescence was distributed into three large patches, the EAC1-3b were at-
tached at these same three points . On the other hand, only 25% of the Cab fluo-
rescence-capped cells contained a rosette cocap when EAC1-3d was used instead
of EAC1-3b . In the other 75% of these C3b fluorescence-capped cells, the EAC1-
3d rosettes either completely surrounded the lymphocytes (independent cap-
ping, Fig . 5 b) or capped at another location on the cell membrane . On most cells
the distribution of the individual attached EAC1-3d seemed to bear no relation-
ship to the distribution of the fluorescence . However, most of the EAC1-3d ro-
settes which were capped were located at a position on the cell membrane which
was rotated 90° or less around the cell from the C3b fluorescence cap, and only
on rare occasions was the EAC1-3d rosette cap observed to be 180° from the
C3b fluorescence cap .
EAC type Rosette
formation
FITC*-labeled
component
Fluorescent
cells
EAC14 48 C4 47
EAC1-3b 57 C3b 52
- - C3c 46
EAC1-3d 67 C3d 571174
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FIG. 5 . Demonstration of independent capping of immune adherence receptors and C3d
receptors . (a) Cocapping : Immune adherence receptors were first labeled by sequential
addition of Cab, rabbit anti-C3, and goat antirabbit 7-globulin conjugated to fluorescein
isothiocyanate . Next, the cells were incubated for 10 minat 37°C to capthe immune adherence
receptors . Then EAC14 was mixed with the lymphocytes for 15 min at 37°C . The EAC14
rosette is cocapped with the Cab fluorescence cap (arrow) showing that complete capping of
immune adherencereceptorshad occurred at the site of the fluorescence cap. (b) Independent
capping : The same procedure as above wasfollowed except that EAC1-3d was used instead of
EAC14. In this case thefluorescence indicated the distribution ofimmune adherence receptors
(indicated by arrow) while the rosette indicated the distribution of Cad receptors .
The tonsil lymphocyte receptors for EAC14 also cocapped (61%) with
fluorescence-labeled Cab . In addition, when bound C4 was fluorescence-labeled
instead of Cab, 80% of C4 fluorescence-capped cells were cocapped with EAC14,
but only 13% were cocapped with EAC1-3d . The remaining 87% of these C4
fluorescence-capped cells contained an EAC1-3d rosette whose orientation was
unrelated to the fluorescence cap . Finally, with caps of fluorescence-labeled C3d
there was 64% cocapping with EAC1-3d rosettes, but only 34% cocapping with
EAC1-3b rosettes and 23% cocapping with EAC14 rosettes .
Discussion
In order to ascertain the number of different types of C receptors on human
lymphocytes and their specificity, experiments were performed in which highly
purified C components or their fragments were tested for their ability to inhibit
rosette formation with EAC . These inhibition studies demonstrated only two
different types ofC receptors and these were shown to be the same two which had
been previously distinguished with antilymphocyte sera (6) . These two receptors
however, were responsible for binding the C contained in three different types of
immune complexes : EAC14, EAC1-3b, and EAC1-3d .
First with normal lymphocytes, it was found that EAC1-3b rosette formation
was inhibited by fluid-phase C4, C3b, C3c, and Cad . However, the degree of
inhibition produced by each inhibitor was different . C4, C3c, and C3d each
produced only partial inhibition of normal lymphocyte EAC1-3b rosette forma-
tion compared to that amount produced by C3b . Since both C3c and C3d
inhibited EAC1-3b rosette formation, it appeared possible that EAC1-3b wereGORDON D. ROSS AND MARGARET J . POLLEY
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bound to two different types of C receptors simultaneously : one specific for the
C3c region of uncleaved C3b, and another specific for the C3d region of uncleaved
C3b . That this was indeed the case was demonstrated by utilizing a mixture of
C3c plus C3d . This mixture produced as much inhibition of EAC1-3b rosette
formation as did an equal protein concentration of C3b, and more inhibition than
did either C3c or C3d alone . Furthermore, fluid-phase C4 could be substituted for
fluid-phase C3c but not for fluid-phase C3d in this EAC1-3b inhibition mixture,
so that it appeared that C4 was bound to the same C3c-region-specific receptor
which bound Cab . Inhibition studies with EAC14 and EAC1-3d rosette formation
confirmed the specificities of these two normal lymphocyte receptors . EAC14
rosette formation was strongly inhibited by fluid-phase C4, C3b, or C3c, but C3d
had no effect on EAC14 rosette formation . Thus it appeared that EAC14 were
only bound to the C3c-region-specific receptors and not to the C3d-region-
specific receptors . On the other hand, EAC1-3d rosette formation was inhibited
by C3b or C3d, but not by Me or C4 . These data indicated that EAC1-3d were
only bound to the C3d-region-specific receptors and not to the C3c-region-
specific receptors .
Similar inhibition assays were also performed to study the specificity of C
receptors on human erythrocytes and two different lines of cultured lymphoblas-
toid cells . Erythrocytes formed rosettes with EAC14 and EAC1-3b, but not with
EAC1-3d . The two lymphoblastoid lines differed from each other in that only one
of the two lines formed significant numbers of rosettes with EAC14, even though
both lines formed rosettes with EAC1-3b and EAC1-3d . With human erythro-
cytes, both EAC1-3b and EAC14 rosette formation were inhibited by fluid-phase
C4, C3b, or C3c, but not by C3d . Thus it appeared that the same erythrocyte
immune adherence receptor was responsible for binding both EAC14 and
EAC1-3b . The inhibition studies however, indicated that the two lymphoblastoid
lines differed qualitatively in their EAC1-3b rosette formation . With the EAC14
rosette-forming line (C . S ., Table III), EAC1-3b rosette formation was primarily
dependent on C3c-region-specific receptors, while in the other line (H . H.-1)
EAC1-3b rosette formation was mainly dependent on C3d-region-specific recep-
tors . These results indicated that EAC1-3b were primarily bound to immune
adherence receptors in the case of the cell line which formed EAC14 rosettes .
Even though this line also contained C3d receptors (as indicated by EAC1-3d
rosette formation), EAC1-3b were mainly bound to immune adherence receptors,
so that fluid-phase C3d had almost no effect on EAC1-3b rosette formation . On
the other hand, in the other cell line, EAC1-3b were mainly bound to C3d
receptors and not to C3c-region-specific (immune adherence) receptors . Since
C3d receptors were not able to bind C4, this latter cell line was not able to form
EAC14 rosettes .
In addition to the specificity studies with fluid-phase C, C receptors were also
examined for inhibition by antisera . The antisera were the same ones which had
been previously used to selectively inhibit either Cab or C3d receptors (6) . The
antierythrocyte serum, which inhibited normal lymphocyte rosette formation
with EAC1-3b but not with EAC1-3d (6), also inhibited lymphocyte rosette
formation with EAC14 . The anti-CLL serum, which inhibited normal lympho-
cyte rosette formation with EAC1-3d but not with EAC1-3b (6), did not have any1176
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effect on EAC14 rosette formation . The antisera were also used to study the C
receptors on two lymphoblastoid lines which formed rosettes with EAC1-3b and
EAC1-3d but not with EAC14 . These two lines (H . H.-1 and Raji) differed
significantly from normal lymphocytes in that theanti-CLL serum inhibited both
EAC1-3b and EAC1-3d rosette formation . Furthermore, with these two cell lines,
the anti-CLL serum produced more inhibition ofEAC1-3b rosette formation than
of EAC1-3d rosette formation . This further confirmed the finding with fluid-
phase C3d that the C3d receptor on certain cell lines was responsible for rosette
formation with both EAC1-3b and EAC1-3d .
From these studies in was concluded that lymphocytes contained only two
different C receptors : the immune adherence receptor and the C3d receptor .
The immune adherence receptor was specific for both C4 and the C3c region of
C3b . The C3d receptor was specific for the C3d produced by Cab inactivator
cleavage of C3b, but would also react to a lesser extent with the C3d region of
uncleaved Cab . With normal lymphocytes which contained both receptors,
EAC1-3b were bound preferentially to immune adherence receptors, though
some simultaneous binding to C3d receptors also occurred . Due to the presence of
some interaction between the C3d receptor and the uncleaved C3b molecule,
certain lines of cultured lymphoblastoid cells which primarily contained C3d
receptors, were able to form rosettes with EAC1-3b as well as with EAC1-3d .
However, many other types of cells which contained onlyC3d receptors were able
to form rosettes only with EAC1-3d and not with EAC1-3b . These latter C3d
receptor-bearing cells were observed in normal tonsils, in certain other lympho-
blastoid lines, and in the peripheral blood of patients with chronic lymphatic
leukemia (6) . Since EAC14 did not react with C3d receptors, EAC14 rosette
formation was thus a more reliable indicator for immune adherence receptors in
the presence of C3d receptors than was EAC1-3b rosette formation .
Recently, Bokisch and Sobel (24) have also described lymphocyte receptors for
C4 and compared the specificity of these receptors to the previously described
C3b receptors . Their data on the inhibition of normal lymphocyte rosette
formation by fluid-phase C was similar to ours in that it demonstrated that C4
was probably bound to the same receptors which bound C3b . However, they did
not conclude that C4 was bound to Cab receptors because the Raji cells which
they also investigated formed rosettes with EAC1-3b but not with EAC14 . This
characteristic of Raji and other similar cell lines appeared to indicate that the C4
receptor might not be the same as the C3b receptor . In the study described
herein, several cell lines similar to Raji were found, and one of them,H .H.-1, was
studied extensively . The explanation for the difference in the binding of C4 and
C3b to lymphocytes was that C3b could be bound to cells containing either the
immune adherence receptor or the C3d receptor, while C4 could only be bound to
lymphocytes containing the immune adherence receptor . Cell lines such as H .
H .-1 and Raji, which contained only C3d receptors, bound Cab, but since they
did not have immune adherence receptors, did not bind C4 . With both H . H.-1
and Raji cells, the involvement of C3d receptors in EAC1-3b rosette formation
was demonstrated by inhibition of EAC1-3b rosette formation with antileukemia
lymphocyte serum . Furthermore, with these C3d receptor-bearing cell lines,
rosette formation with EAC1-3b was shown to be much weaker than withGORDON D. ROSS AND MARGARET J. POLLEY
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EAC1-3d. EAC1-3b rosette formation was inhibited by a lower concentration of
either fluid-phase C3d or antileukemic lymphocyte serum than was EAC1-3d ro-
sette formation. Indeed, EAC1-3d rosette formation with H. H.-1 cells was so
strong that inhibition required at least 10 x 10-'M C3d, and inhibition by
fluid-phase C3b was difficult to demonstrate at all. This probably explains why
Theofilopoulos et al. (25) found that with Raji cells, C3b inhibited EAC1-3b
rosette formation but not EAC1-3d rosette formation. With normal lymphocytes
and cell lines which formed weaker EAC1-3d rosettes, as little as 5 x 10- BM Cab
inhibited EAC1-3d rosette formation.
Previously it was shown that patients with CLL had lymphocytes with C3d
receptors but had diminished numbers of lymphocytes with immune adherence
receptors (6). Data obtained in the present study which utilized EAC14 to assay
immune adherence receptors agree well with that previous finding in that few
lymphocytes from these patients formed rosettes with EAC14. Furthermore,
antiserum to leukemic lymphocytes did not inhibit EAC14. Lymphocytes from
three patients with Waldenstrom's macroglobulinemia differed from CLL lym-
phocytes in that they appeared to contain immune adherence receptors but di-
minished amounts of C3d receptors. Lymphocytes from patients with CLL also
occasionally lack SIg (9). Such lymphocytes, having C3d receptors but lacking
SIg and immune adherence receptors, have not been observed in normal blood,
spleen, or thoracic duct (9), but in this study were observed to make up a signifi-
cant proportion of tonsil lymphocytes.
Purified C components and their fragments were bound sufficiently firmly to C
receptors on normal lymphocytes to allow their detection by indirect immuno-
fluorescence. Similar fluorescence staining of C receptors on cells from the Raji
lymphoblastoid line had been previously reported (26) . The distribution of
fluorescence-labeled C receptors was found to depend on labeling conditions in a
manner similar to that reported for SIg (27) . In ourstudy, simultaneous detection
of the two different C receptors on individual cells was accomplished by utilizing
fluorescence to distinguish one type of receptor and EAC rosette formation to
distinguish the other type. This technique permitted a study of the physical
interrelationships of the two differentreceptors. It was found that 61-80% of cells
containing caps of fluorescence-labeled C3b or C4 also contained immediately
adjacent rosette caps of either EAC1-3b or EAC14 (cocapping). In contrast to this
finding, only 13-25% of the cells with C3b or C4 fluorescence caps were cocapped
with EAC1-3d rosettes. In the remaining 75-87% of these C3b or C4 fluorescence-
capped cells, the EAC1-3d rosette either completely surrounded the cell or was
capped at a location on the cell membrane that was rotated90° or less around the
cell membrane from the fluorescence cap. The ability of the immune adherence
receptor and the C3d receptor to each cap independently of the other indicated
that each was located on different molecules, each of which could move through
the fluid membrane matrix independently of the other. Furthermore, it was of
interest that both types of receptors were able to bind EAC after they had been
fluorescence-labeled and capped . Much of the C bound from the fluid phasewas
removed by the washing steps during the fluorescence-labeling procedure and
this permitted EAC rosette formation with the fluorescence-labeled cells.
However, even though the remaining fluorescence-labeled C was insufficient to1178
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inhibit rosette formation, it was able to cap almost all of the C receptors
detectable by rosette formation. That the two types of fluorescence-capped
receptor molecules were able to bind EAC, and almost always at the location of
the fluorescence cap, indicatesthat both types of receptor molecules are probably
multivalent.
The identification of C4 receptor activity on lymphoid cells and phagocytic
cells demonstrates an activity for complex-bound C4 that was not previously
recognized. This activity appearsto be the same as the C4-dependent erythrocyte
immune adherence originally described by Cooper (4). The C4 receptor activity
of the immune adherence receptor may have more significance in vivo than the
C3b activity of the receptor, since complex-bound C4, but not C3b, is protected
from the action of C3b inactivator by the presence of C2 (N. R. Cooper, personal
communication) . In experiments performed with granulocytes, it was found that
small amounts of bound C4 were sufficient for rosette formation and would
greatly enhance the phagocytosis of EAy, (28) . Since monocytes required much
more bound C4 than did granulocytes for rosette formation, it may be significant
that monocytes, but not granulocytes (6), were found to have receptors for
complex-bound C3d. Furthermore, in other studies the C3d receptors on
monocytes were found to enhance the phagocytosis of erythrocytes in a similar
manner as did the C4 receptors on granulocytes .'
Summary
Erythrocytes, bone marrow-derived lymphocytes, monocytes, and granulocytes
were shown to have a receptor activity for C4. This C4 receptor activity was
studied in relation to the previously identified C3b and C3d receptors. By assay
for inhibition of rosette formation by fluid-phase complement (C), only two
different lymphocyte C receptors were demonstrated. The immune adherence
receptor, the only one of the two shared in common with erythrocytes, was
specific for C4 or the C3c region of C3b, but was unreactive with C3d. The other
lymphocyte receptor, the C3d receptor, was specific for C3d fragments, but would
also react to a lesser extent with the C3d region of uncleaved C3b. The C3d
receptor did not react with either C3c or C4. This specificity of the C3d receptor
allowed certain cells which contained only C3d receptors to form rosettes with
EAC1-3b and EAC1-3d, but not with EAC14. However, because C3d receptors
bound EAC1-3d or C3d fragments more firmly than they did EAC1-3b or Cab
fragments, many other types of cells containing only C3d receptors, formed
rosettes with EAC1-3d but not with EAC1-3b. Erythrocytes and those lympho-
cytes which contained only immune adherence receptors, formed rosettes with
EAC14 and EAC1-3b but not with EAC1-3d. A double-label assay was devised
for the simultaneous detection of both types of C receptors on individual
lymphocytes. This assay involved fluorescence labeling of one of the two C
receptors with soluble C fragments in combination with the usual rosette method
for labeling the other type of C receptor. With this double-label assay, it was
observed that the two different lymphocyte C receptors capped independently
and thus were located on different molecules which could each move through the
fluid membrane matrix independently of the other.
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